Current pharmacotherapy for gambling disorder: a systematic review

References

• Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®). Washington, DC, USA: American Psychiatric Pub; 2013.
   Google Scholar
• Grant JE, Kim SW. Quality of life in kleptomania and pathological gambling. Compr Psychiatry. 2005;46(1):34–37.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Hwang I, LaBrie R, et al. DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychol Med. 2008;38(9):1351–1360.
   PubMed Web of Science ®Google Scholar
• Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.[CME]. J Clin Psychiatry. 2005;66(5):1,478–574.
   Web of Science ®Google Scholar
• Petry NM, Zajac K, Ginley M, et al. Policy and prevention efforts for gaming should consider a broad perspective: commentary on: policy responses to problematic video game use: a systematic review of current measures and future possibilities (Király et al., 2018). J Behav Addict. 2018;7(3):543–547.
   PubMedGoogle Scholar
• Toce-Gerstein M, Gerstein DR, Volberg RA. The NODS–cLiP: a rapid screen for adult pathological and problem gambling. J Gambl Stud. 2009;25(4):541.
   PubMed Web of Science ®Google Scholar
• Welte JW, Barnes GM, Tidwell M-CO, et al. Gambling and problem gambling in the United States: changes between 1999 and 2013. J Gambl Stud. 2015;31(3):695–715.
   PubMed Web of Science ®Google Scholar
• Alegría AA, Petry NM, Hasin DS, et al. Disordered gambling among racial and ethnic groups in the US: results from the National Epidemiologic Survey on Alcohol and Related Conditions. CNS Spectr. 2009;14(3):132–143.
   PubMed Web of Science ®Google Scholar
• Johansson A, Grant JE, Kim SW, et al. Risk factors for problematic gambling: a critical literature review. J Gambl Stud. 2009;25(1):67–92.
   PubMed Web of Science ®Google Scholar
• Kong G, Smith PH, Pilver C, et al. Problem-gambling severity and psychiatric disorders among American-Indian/Alaska native adults. J Psychiatr Res. 2016;74:55–62.
   PubMed Web of Science ®Google Scholar
• Shirk SD, Kelly MM, Kraus SW, et al. Gambling‐related cognitive distortions predict level of function among US veterans seeking treatment for gambling disorders. Am J Addict. 2018;27(2):108–115.
   PubMed Web of Science ®Google Scholar
• Welte JW, Barnes GM, Wieczorek WF, et al. Risk factors for pathological gambling. Addict Behav. 2004;29(2):323–335.
   PubMed Web of Science ®Google Scholar
• Desai RA, Desai MM, Potenza MN. Gambling, health and age: data from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Addict Behav. 2007 Dec;21(4):431–440.
   PubMed Web of Science ®Google Scholar
• Pilver CE, Libby DJ, Hoff RA, et al. Problem gambling severity and the incidence of Axis I psychopathology among older adults in the general population. J Psychiatr Res. 2013;47(4):534–541.
   PubMed Web of Science ®Google Scholar
• Morasco BJ, Pietrzak RH, Blanco C, et al. Health problems and medical utilization associated with gambling disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2006;68(6):976–984.
   PubMed Web of Science ®Google Scholar
• Ronzitti S, Kraus SW, Hoff RA, et al. Stress moderates the relationships between problem-gambling severity and specific psychopathologies. Psychiatry Res. 2018;259:254–261.
   PubMed Web of Science ®Google Scholar
• Cowlishaw S, Hakes JK. Pathological and problem gambling in substance use treatment: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Am J Addict. 2015;24(5):467–474.
   PubMed Web of Science ®Google Scholar
• Ronzitti S, Kraus SW, Decker SE, et al. Clinical characteristics of veterans with gambling disorders seeking pain treatment. Addict Behav. 2019;95:160–165.
   PubMed Web of Science ®Google Scholar
• Ronzitti S, Kraus SW, Hoff RA, et al. Problem-gambling severity, suicidality and DSM-IV Axis II personality disorders. Addict Behav. 2018;82:142–150.
   PubMed Web of Science ®Google Scholar
• Dannon PN, Lowengrub K, Gonopolski Y, et al. Pathological gambling: a review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder. Prim Care Companion J Clin Psychiatry. 2006;8(6):334.
   PubMedGoogle Scholar
• Desai RA, Potenza MN. Gender differences in the associations between past-year gambling problems and psychiatric disorders. Soc Psychiatry Psychiatr Epidemiol. 2008;43(3):173–183.
   PubMed Web of Science ®Google Scholar
• Brewer JA, Potenza MN, Desai RA. Differential associations between problem and pathological gambling and psychiatric disorders in individuals with and without alcohol abuse or dependence. CNS Spectr. 2010;15(1):33–44.
   PubMed Web of Science ®Google Scholar
• Cox S, Lesieur HR, Rosenthal RJ, et al. Problem and pathological gambling in America: The national picture. Columbia, MD: National Council on Problem Gambling; 1997.
   Google Scholar
• Ledgerwood DM, Steinberg MA, Wu R, et al. Self-reported gambling-related suicidality among gambling helpline callers. Psychol Addict Behav. 2005;19(2):175.
   PubMed Web of Science ®Google Scholar
• Petry NM, Kiluk BD. Suicidal ideation and suicide attempts in treatment-seeking pathological gamblers. J Nerv Ment Dis. 2002;190(7):462.
   PubMed Web of Science ®Google Scholar
• Ledgerwood DM, Milosevic A. Clinical and personality characteristics associated with post traumatic stress disorder in problem and pathological gamblers recruited from the community. J Gambl Stud. 2015;31(2):501–512.
   PubMed Web of Science ®Google Scholar
• Slutske WS. Natural recovery and treatment-seeking in pathological gambling: results of two US national surveys. Am J Psychiatry. 2006;163(2):297–302.
   PubMed Web of Science ®Google Scholar
• Bernardi S, Petry NM, Martins SS, et al. Predictors of remission from problem and pathological gambling: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Milan, Italy: Archives of Behavioral Addictions; 2019.
   Google Scholar
• Bartley CA, Bloch MH. Meta-analysis: pharmacological treatment of pathological gambling. Expert Rev Neurother. 2013 Aug;13(8):887–894.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008 May;69(5):783–789.
   PubMed Web of Science ®Google Scholar
• Yip SW, Potenza MN. Treatment of gambling disorders. Curr Treat Options Psychiatry. 2014;1(2):189–203.
   PubMedGoogle Scholar
• Toneatto T, Ladoceur R. Treatment of pathological gambling: a critical review of the literature. Psychol Addict Behav. 2003;17(4):284.
   PubMed Web of Science ®Google Scholar
• Petry NM, Weinstock J, Ledgerwood DM, et al. A randomized trial of brief interventions for problem and pathological gamblers. J Consult Clin Psychol. 2008;76(2):318.
   PubMed Web of Science ®Google Scholar
• Petry NM, Rash CJ, Alessi SM. A randomized controlled trial of brief interventions for problem gambling in substance abuse treatment patients. J Consult Clin Psychol. 2016 Oct;84(10):874–886.
   PubMed Web of Science ®Google Scholar
• Potenza MN, Balodis IM, Derevensky J, et al. Gambling disorder. Nat Rev Dis Primers. 2019;5(1):51.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Schreiber LR. Pharmacological treatments in pathological gambling. Br J Clin Pharmacol. 2014;77(2):375–381.
   PubMed Web of Science ®Google Scholar
• Achab S, Khazaal Y. Psychopharmacological treatment in pathological gambling: a critical review. Curr Pharm Des. 2011;17(14):1389–1395.
   PubMed Web of Science ®Google Scholar
• Medeiros GC, Grant JE. Pharmacological interventions in gambling disorder. In: Heinz A, Romanczuk-Seiferth N, Potenza M, editors. Gambling disorder. Cham, Switzerland: Springer; 2019. p. 171–180.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–341.
   PubMed Web of Science ®Google Scholar
• American Psychiatric A. Diagnostic and statistical manual-text revision (DSM-IV-TRim, 2000). Arlington, VA: American Psychiatric Association; 2000.
   Google Scholar
• Lesieur HR, Blume SB. The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry. 1987;144(9):1184–1188.
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical Global Impressions Scale. In ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Pub. No. ADM 76-338; pp. 218–222). Rockville, MD: National Institute for Mental Health; 1976.
   Google Scholar
• Pallanti S, DeCaria CM, Grant JE, et al. Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambl Stud. 2005;21(4):431–443.
   PubMed Web of Science ®Google Scholar
• Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914–921.
   PubMed Web of Science ®Google Scholar
• Lasa L, Ayuso-Mateos J, Vazquez-Barquero J, et al. The use of the Beck Depression Inventory to screen for depression in the general population: a preliminary analysis. J Affect Disord. 2000;57(1–3):261–265.
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55.
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56–62.
   PubMed Web of Science ®Google Scholar
• Bosco D, Plastino M, Colica C, et al. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol. 2012;35(3):118–120.
   PubMed Web of Science ®Google Scholar
• Dannon PN, Lowengrub K, Musin E, et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol. 2005;25(6):593–596.
   PubMed Web of Science ®Google Scholar
• Kovanen L, Basnet S, Castren S, et al. A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling. Eur Addict Res. 2016;22(2):70–79.
   PubMed Web of Science ®Google Scholar
• Lahti T, Halme JT, Pankakoski M, et al. Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacol Bull. 2010;43(3):35–44.
   PubMedGoogle Scholar
• Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict. 2009;18(3):219–225.
   PubMed Web of Science ®Google Scholar
• Fattore L, Diana M. Drug addiction: an affective-cognitive disorder in need of a cure. Neurosci Biobehav Rev. 2016;65:341–361.
   PubMed Web of Science ®Google Scholar
• Moccia L, Pettorruso M, De Crescenzo F, et al. Neural correlates of cognitive control in gambling disorder: a systematic review of fMRI studies. Neurosci Biobehav Rev. 2017;78:104–116.
   PubMed Web of Science ®Google Scholar
• Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006 Feb;163(2):303–312.
   PubMed Web of Science ®Google Scholar
• Grant J, Odlaug B, Potenza M, et al. A multi-center, double-blind, placebocontrolled study of the opioid antagonist nalmefene in the treatment of pathological gambling. Br J Psychiatry. 2010;197:330–331.
   PubMed Web of Science ®Google Scholar
• Potenza MN, Hollander E. Pathological gambling and impulse control disorders. In: Neuropsychopharmacology: the 5th generation of 2002. Citeseer; 2002.
   Google Scholar
• Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry. 2000 May 1;47(9):813–817.
   PubMed Web of Science ®Google Scholar
• Blanco C, Petkova E, Ibáñez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14(1):9–15.
   PubMedGoogle Scholar
• Kim SW, Grant JE, Adson DE, et al. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002 Jun;63(6):501–507.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol. 2003;18(4):243–249.
   PubMed Web of Science ®Google Scholar
• Saiz-Ruiz J, Blanco C, Ibáñez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry. 2005;66(1):28–33.
   PubMed Web of Science ®Google Scholar
• Black DW, Arndt S, Coryell WH, et al. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol. 2007;27(2):143–150.
   PubMed Web of Science ®Google Scholar
• Stewart RS, Nejtek VA. An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2003;64(1):49–52.
   PubMed Web of Science ®Google Scholar
• Christensen RC. Olanzapine augmentation of fluoxetine in the treatment of pathological skin picking. Can J Psychiatry. 2004;49(11):788.
   PubMed Web of Science ®Google Scholar
• Fong T, Kalechstein A, Bernhard B, et al. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav. 2008;89(3):298–303.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Nelson EB, Welge JA, et al. Olanzapine in the, treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008;69(3):433–440.
   PubMed Web of Science ®Google Scholar
• Mandelli L, Mazza M, Di Nicola M, et al. Role of substance abuse comorbidity and personality on the outcome of depression in bipolar disorder: harm avoidance influences medium-term treatment outcome. Psychopathology. 2012;45(3):174–178.
   PubMed Web of Science ®Google Scholar
• Swann AC. The strong relationship between bipolar and substance‐use disorder: mechanisms and treatment implications. Ann N Y Acad Sci. 2010;1187(1):276–293.
   PubMedGoogle Scholar
• Di Nicola M, De Risio L, Pettorruso M, et al. Bipolar disorder and gambling disorder comorbidity: current evidence and implications for pharmacological treatment. J Affect Disord. 2014;167:285–298.
   PubMed Web of Science ®Google Scholar
• Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162(1):137–145.
   PubMed Web of Science ®Google Scholar
• Berlin HA, Braun A, Simeon D, et al. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry. 2013;14(2):121–128.
   PubMed Web of Science ®Google Scholar
• Knackstedt LA, Kalivas PW. Glutamate and reinstatement. Curr Opin Pharmacol. 2009;9(1):59–64.
   PubMed Web of Science ®Google Scholar
• Schmaal L, Berk L, Hulstijn KP, et al. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res. 2011;17(4):211–216.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62(6):652–657.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Chamberlain SR, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry. 2014;75(1):39–45.
   PubMed Web of Science ®Google Scholar
• de Brito AMC, de Almeida Pinto MG, Bronstein G, et al. Topiramate combined with cognitive restructuring for the treatment of gambling disorder: a two-center, randomized, double-blind clinical trial. J Gambl Stud. 2017;33(1):249–263.
   PubMed Web of Science ®Google Scholar
• Starosta AN, Leeman RF, Volpicelli JR. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract. 2006;12(2):80.
   PubMedGoogle Scholar
• Gooding P, Tarrier N. A systematic review and meta-analysis of cognitive-behavioural interventions to reduce problem gambling: hedging our bets? Behav Res Ther. 2009;47(7):592–607.
   PubMed Web of Science ®Google Scholar
• Pallesen S, Molde H, Arnestad HM, et al. Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis. J Clin Psychopharmacol. 2007;27(4):357–364.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Carlino E, Pollo A. How placebos change the patient’s brain. Neuropsychopharmacology. 2011;36(1):339.
   PubMed Web of Science ®Google Scholar
• Spagnolo PA, Colloca L, Heilig M. The role of expectation in the therapeutic outcomes of alcohol and drug addiction treatments. Alcohol Alcohol. 2015;50(3):282–285.
   PubMed Web of Science ®Google Scholar
• Potenza MN. The neural bases of cognitive processes in gambling disorder. Trends Cogn Sci. 2014;18(8):429–438.
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Hollander E, et al. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl). 2008;200(4):521–527.
   PubMed Web of Science ®Google Scholar
• Bullock SA, Potenza MN. Pathological gambling: neuropsychopharmacology and treatment. Current Psychopharmacology. 2012;1(1):67–85.
   Google Scholar
• Grant JE, Potenza MN, Kraus SW, et al. Naltrexone and disulfiram treatment response in veterans with alcohol dependence and co-occurring problem-gambling features. J Clin Psychiatry. 2017 Nov/Dec;78(9):e1299–e306.
   PubMed Web of Science ®Google Scholar
• Nower L, Martins SS, Lin KH, et al. Subtypes of disordered gamblers: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Addiction. 2013;108(4):789–798.
   PubMed Web of Science ®Google Scholar
• Pickering D, Keen B, Entwistle G, et al. Measuring treatment outcomes in gambling disorders: a systematic review. Addiction. 2018;113(3):411–426.
   PubMed Web of Science ®Google Scholar
• Ginley MK, Rash CJ, Petry NM. Psychological interventions in gambling disorder. In: Heinz A, Romanczuk-Seiferth N, Potenza M, editors. Gambling disorder. Cham, Switzerland: Springer; 2019. p. 181–194.
   Google Scholar
• Science has a gambling problem. Nature. 2018;553:379.
   Google Scholar
• Potenza MN, Higuchi S, Brand M. Call for research into a wider range of behavioural addictions. Nature. 2018;555:7694.
   Google Scholar
• St-Pierre RA, Walker DM, Derevensky J, et al. How availability and accessibility of gambling venues influence problem gambling: a review of the literature. Gaming Law Rev Econ. 2014;18(2):150–172.
   Google Scholar
• Welte JW, Barnes GM, Tidwell M-CO, et al. Legal gambling availability and problem gambling among adolescents and young adults. Int Gambl Stud. 2009;9(2):89–99.
   Google Scholar
• Welte JW, Tidwell M-CO, Barnes GM, et al. The relationship between the number of types of legal gambling and the rates of gambling behaviors and problems across US states. J Gambl Stud. 2016;32(2):379–390.
   PubMed Web of Science ®Google Scholar